JP2023540206A5 - - Google Patents

Info

Publication number
JP2023540206A5
JP2023540206A5 JP2023512718A JP2023512718A JP2023540206A5 JP 2023540206 A5 JP2023540206 A5 JP 2023540206A5 JP 2023512718 A JP2023512718 A JP 2023512718A JP 2023512718 A JP2023512718 A JP 2023512718A JP 2023540206 A5 JP2023540206 A5 JP 2023540206A5
Authority
JP
Japan
Prior art keywords
lymphoma
pharmaceutical composition
composition according
anticancer agent
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023512718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540206A (ja
JP7734742B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/047778 external-priority patent/WO2022047051A1/en
Publication of JP2023540206A publication Critical patent/JP2023540206A/ja
Publication of JP2023540206A5 publication Critical patent/JP2023540206A5/ja
Application granted granted Critical
Publication of JP7734742B2 publication Critical patent/JP7734742B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023512718A 2020-08-27 2021-08-26 癌併用療法におけるdhodh阻害剤化合物の利用 Active JP7734742B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070984P 2020-08-27 2020-08-27
US63/070,984 2020-08-27
PCT/US2021/047778 WO2022047051A1 (en) 2020-08-27 2021-08-26 Use of a dhodh inhibitor compound in combination cancer therapy

Publications (3)

Publication Number Publication Date
JP2023540206A JP2023540206A (ja) 2023-09-22
JP2023540206A5 true JP2023540206A5 (cg-RX-API-DMAC7.html) 2024-09-02
JP7734742B2 JP7734742B2 (ja) 2025-09-05

Family

ID=78000775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512718A Active JP7734742B2 (ja) 2020-08-27 2021-08-26 癌併用療法におけるdhodh阻害剤化合物の利用

Country Status (9)

Country Link
US (1) US20230285365A1 (cg-RX-API-DMAC7.html)
EP (1) EP4203950B1 (cg-RX-API-DMAC7.html)
JP (1) JP7734742B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230078997A (cg-RX-API-DMAC7.html)
CN (1) CN116847874B (cg-RX-API-DMAC7.html)
BR (1) BR112023003493A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190511A1 (cg-RX-API-DMAC7.html)
ES (1) ES3063941T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022047051A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060390A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
BR112021012305A2 (pt) * 2018-12-21 2021-10-05 Les Laboratoires Servier Sas Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2694829T3 (es) 2013-02-25 2018-12-27 Aurigene Discovery Technologies Limited Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
CN106687139A (zh) * 2014-07-14 2017-05-17 吉利德科学公司 用于治疗癌症的组合
WO2016166761A1 (en) * 2015-04-14 2016-10-20 Tiltan Pharma Ltd. Combination therapies and uses thereof in the treatment of cancer
CA3060390A1 (en) * 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US20180369206A1 (en) * 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CA3091792A1 (en) * 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
WO2019197269A1 (en) * 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
KR20210003789A (ko) * 2018-05-04 2021-01-12 포톨라 파마슈티컬스, 인코포레이티드 림프종을 치료하는 방법
WO2020109625A1 (en) * 2018-11-30 2020-06-04 Fondazione Centro San Raffaele Combined treatment of primary central nervous system lymphoma
BR112021012305A2 (pt) * 2018-12-21 2021-10-05 Les Laboratoires Servier Sas Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas

Similar Documents

Publication Publication Date Title
JP6510075B2 (ja) バイオアベイラビリティが高いアルボシジブプロドラッグ
JP2020097577A5 (cg-RX-API-DMAC7.html)
JP2018534286A5 (cg-RX-API-DMAC7.html)
JP2009502743A5 (cg-RX-API-DMAC7.html)
JP2017518334A5 (cg-RX-API-DMAC7.html)
JP2022516974A5 (cg-RX-API-DMAC7.html)
JP2005537854A5 (cg-RX-API-DMAC7.html)
CN108350016B (zh) 抗病毒四氢呋喃衍生物
US20190263802A1 (en) Compounds and method of use
JP2021530444A5 (cg-RX-API-DMAC7.html)
JP2006507265A5 (cg-RX-API-DMAC7.html)
CN105367482A (zh) N-酰基磺酰胺凋亡促进剂
JP2017537969A5 (cg-RX-API-DMAC7.html)
JP2006504766A5 (cg-RX-API-DMAC7.html)
JP2008505157A5 (cg-RX-API-DMAC7.html)
JP2024520630A5 (cg-RX-API-DMAC7.html)
JP2006503850A5 (cg-RX-API-DMAC7.html)
BR112019017962A2 (pt) método para inibição de crescimento, de migração, de proliferação e/ou de metástase de uma célula pré-cancerosa, cancerosa ou neoplásica ou de inibição de um patógeno, composição probiótica tópica, bandagem ou curativo, método de tratamento de dano na pele devido à radiação uv, e, composição farmacêutica
JP2022535609A5 (cg-RX-API-DMAC7.html)
JP2007502832A5 (cg-RX-API-DMAC7.html)
JP2023513793A5 (cg-RX-API-DMAC7.html)
JP2024542984A5 (cg-RX-API-DMAC7.html)
RU2003134629A (ru) Соединения цефема
JP2024538730A5 (cg-RX-API-DMAC7.html)
JP2004529172A5 (cg-RX-API-DMAC7.html)